title: Transplanting the highly sensitized patient: The emory algorithm.
abstract: Renal transplant patients sensitized to HLA antigens comprise nearly one-third of the UNOS wait-list and receive 14% of deceased donor (DD) transplants, a rate half that of unsensitized patients. Between 1999 and 2003, we performed 492 adult renal transplants from DD; 120 patients (approximately 25%) had a panel reactive antibody (PRA) of >30%, with nearly half (n = 58) having a PRA of >80%. Our approach is based upon high-resolution solid-phase HLA antibody analysis to identify class I/II antibodies and a 'virtual crossmatch' to predict compatible donor/recipient combinations. Recipients are excluded from the United Network for Organ Sharing match run if donors possess unacceptable antigens. Thus, when sensitized patients appear on the match run, they have a high probability of a negative final crossmatch. Here, we describe our 5-year experience with this approach. Five-year graft survival ranged from 66% to 70% among unsensitized (n = 272), moderately sensitized (PRA < 30%, n = 100) and highly sensitized (>30% PRA; n = 120) patients, equal to the average national graft survival (65.7%). The application of this approach (the Emory Algorithm) provides a logical and systematic approach to improve the access of sensitized patients to DD organs and promote more equitable allocation to a highly disadvantaged group of patients awaiting renal transplantation.
authors.affiliation: Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, USA.
authors.forename: R A
authors.initials: RA
authors.lastname: Bray
authors.forename: J D L
authors.initials: JD
authors.lastname: Nolen
authors.forename: C
authors.initials: C
authors.lastname: Larsen
authors.forename: T
authors.initials: T
authors.lastname: Pearson
authors.forename: K A
authors.initials: KA
authors.lastname: Newell
authors.forename: K
authors.initials: K
authors.lastname: Kokko
authors.forename: A
authors.initials: A
authors.lastname: Guasch
authors.forename: P
authors.initials: P
authors.lastname: Tso
authors.forename: J B
authors.initials: JB
authors.lastname: Mendel
authors.forename: H M
authors.initials: HM
authors.lastname: Gebel
mesh_terms: D000465:Algorithms; D001402:B-Lymphocytes / Q000276:immunology*; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007114:Immunization / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D013601:T-Lymphocytes / Q000276:immunology*; D014184:Transplantation, Homologous
chemical_list: D006680:HLA Antigens; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D007166:Immunosuppressive Agents